STOCKS TELEGRAPH

Tag: Vivos Therapeutics

  • 3 Stocks That Could See Trading Interest: Vivos Therapeutics (VVOS), Cardiol Therapeutics (CRDL), Dare Bioscience (DARE)

    3 Stocks That Could See Trading Interest: Vivos Therapeutics (VVOS), Cardiol Therapeutics (CRDL), Dare Bioscience (DARE)

    Healthcare and biotechnology stocks continue to attract investor attention as companies advance clinical programs, pursue regulatory milestones, and work toward commercial expansion. While market fluctuations remain common across the sector, developments related to product pipelines, financial performance, and strategic initiatives often play a significant role in shaping investor sentiment and long-term growth expectations.

    Vivos Therapeutics Inc (VVOS)

    Vivos Therapeutics Inc (NASDAQ: VVOS) flaunted a slowness of -0.99% at $0.68, as the Stock market unbolted on June 02, 2026. During the day, the stock rose to $0.73 and sunk to $0.65. Taking a more long-term approach, VVOS posted a 52-week range of $0.55-$7.95.

    The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 39.15%. Meanwhile, its Annual Earning per share during the time was 39.15%.  Nevertheless, stock’s Earnings Per Share (EPS) this year is 40.10%. This publicly-traded company’s shares outstanding now amounts to $13.49 million, simultaneously with a float of $10.14 million. The organization now has a market capitalization sitting at $9.42 million.

    Cardiol Therapeutics Inc. (CRDL)

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) is continuing to broaden its cardiovascular pipeline by pursuing therapies for inflammatory heart diseases that currently have limited targeted treatment options. This diversification strategy is important because it allows the company to build value beyond a single clinical program while leveraging its expertise in cardiovascular inflammation.

    Market Momentum

    As of June 2, 2026, CRDL closed at $1.15, down 5.74%, with trading volume of 409,173 shares versus an average volume of 677,258 shares. The company currently carries a market capitalization of $132.563M and a beta of 0.43, reflecting relatively controlled volatility compared with many development-stage biotechnology companies. Shares continue trading within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.29 suggests substantial upside potential if the company successfully executes its clinical strategy.

    ARCHER and Acute Myocarditis

    Beyond recurrent pericarditis, Cardiol has generated encouraging data through its Phase II ARCHER trial evaluating CardiolRx™ in acute myocarditis. This disease involves inflammation of the heart muscle and can result in impaired cardiac function, arrhythmias, and long-term cardiovascular complications. Clinical findings demonstrated favorable effects on markers of cardiac inflammation and structural measures associated with heart health, supporting continued interest in the program.

    Broadening the Clinical Opportunity

    Success in myocarditis could significantly expand Cardiol’s addressable market while validating the broader applicability of its anti-inflammatory platform. Importantly, positive results across multiple cardiovascular conditions strengthen the scientific hypothesis that targeting inflammation may provide meaningful therapeutic benefits beyond a single indication. This platform potential is often viewed favorably by long-term investors seeking multiple pathways to value creation.

    Outlook

    While MAVERIC remains the company’s lead value driver, the ARCHER program demonstrates that Cardiol’s opportunity extends beyond recurrent pericarditis. Additional progress in myocarditis could enhance the company’s growth profile, diversify development risk, and create future opportunities across a wider range of inflammatory cardiovascular diseases.

    Dare Bioscience Inc (DARE)

    Dare Bioscience Inc (NASDAQ: DARE) started the day on June 02, 2026, with a price decrease of -2.28% at $2.14. During the day, the stock rose to $2.22 and sunk to $2.13. Taking a more long-term approach, DARE posted a 52-week range of $1.27-$9.19.

    The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 35.73%. Meanwhile, its Annual Earning per share during the time was 35.73%.  Nevertheless, stock’s Earnings Per Share (EPS) this year is 21.11%. This publicly-traded company’s shares outstanding now amounts to $14.56 million, simultaneously with a float of $13.73 million. The organization now has a market capitalization of $32.06 million.

  • Pre-Market Momentum Builds For Vivos Therapeutics (VVOS) Following Key Developments

    Pre-Market Momentum Builds For Vivos Therapeutics (VVOS) Following Key Developments

    Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares are experiencing a significant rise on the US stock charts, witnessing a 5.37% increase during the pre-market session, reaching $2.55. This upward trend in VVOS stock is attributed to a pivotal announcement that has invigorated investor interest and optimism surrounding the company’s future.

    AMA Issues New CPT Codes

    Vivos (VVOS) has announced that new Current Procedural Terminology (CPT) codes have been created by the American Medical Association (AMA) and are applicable to all Vivos CARE oral medical devices. These codes will go into effect on January 1, 2025.

    For individuals with obstructive sleep apnea (OSA) and the medical professionals who treat them, this announcement is very significant. The launch of these codes will improve coverage and payment prospects from commercial insurance companies. Vivos’s CARE oral medical devices are the only FDA-cleared devices intended to treat moderate to severe OSA.

    Enhanced Patient Accessibility

    The issuance of these new CPT codes is anticipated to expand access to Vivos’s proprietary airway remodeling technology, allowing a broader demographic of patients to effectively manage their OSA.

    This strategic timing aligns well with Vivos’s recent regulatory approvals and a newly established alliance-based marketing and distribution model, positioning the company to foster substantial revenue growth.

    Implications of CPT 2025 Updates

    The AMA highlighted that advancements in medical innovations and technologies largely drive the updates reflected in the CPT 2025 code set, which includes a total of 420 revisions—270 new codes, 112 deletions, and 38 modifications.

    This code set serves as a cornerstone for the efficient exchange of standardized information within a data-driven healthcare system, ultimately aiming to improve patient care, enhance clinical outcomes, and reduce costs.

    The approval of these new CPT codes marks a significant regulatory and reimbursement milestone for Vivos, building upon the recent Medicare coverage approval the company received.

    This progress underscores VVOS’s dedication to making OSA treatment more accessible and affordable, especially for younger patients aged 6 to 17, while ensuring that individuals receive the necessary support from their healthcare insurance plans.

  • Vivos (VVOS) Stock Rallies In Pre-Hours Trading Following Key Regulatory Approval

    Vivos (VVOS) Stock Rallies In Pre-Hours Trading Following Key Regulatory Approval

    Vivos Therapeutics, Inc. (NASDAQ: VVOS) is seeing a notable increase in its stock value on the US stock charts today, up 22.14% to $3.42 as of the latest pre-market check. This substantial gain follows the recent announcement of a pivotal regulatory approval.

    Vivos Received Breakthrough FDA Clearance

    With the help of its patented oral medical device, Vivos Therapeutics has received what is regarded as the first-ever FDA 510(k) approval for treating moderate to severe obstructive sleep apnea (OSA) and snoring in children. With its approval, the range of treatments for children sleep problems has significantly expanded.

    Prevalence and Impact of Pediatric OSA

    Based on recent research, 10.1 million children in the United States between the ages of 6 and 17 suffer with pediatric OSA, which falls under the category of sleep-related breathing disorders (SRBD). This number represents the more than doubling of instances throughout the previous ten years. Notably, up to 95% of juvenile OSA patients have signs of attention deficit disorders (ADD/ADHD), for which psychiatric drugs are commonly used as a treatment.

    Market Opportunity and Strategic Plans

    Current standard treatments for pediatric OSA typically involve surgical removal of adenoids and/or tonsils (adenotonsillectomy). However, this approach has shown a relapse rate of 21% to 73% and mixed long-term benefits.

    Additionally, continuous positive airway pressure (CPAP) therapy is not widely recommended for children due to potential adverse effects on normal cranial and facial development. Vivos Therapeutics views this FDA clearance as a major opportunity to capture a substantial market share in a field in dire need of innovative and effective treatments.

    The company plans to capitalize on this regulatory achievement by integrating pediatric care into its new provider-based marketing and distribution model. This strategy aims to rapidly scale revenue with minimal investment, leveraging Vivos’ strong case acceptance and its alliances with medical sleep care professionals.

    Global Impact and Future Prospects

    This FDA clearance is the latest in a series of regulatory successes for Vivos Therapeutics (VVOS), extending beyond the U.S. to global markets. It underscores the growing recognition of Vivos’ technology and opens up a vast new market for addressing the needs of millions of children suffering from sleep-related breathing disorders such as OSA.

  • Why VVOS Stock Topping Charts in the Pre Market Today

    Why VVOS Stock Topping Charts in the Pre Market Today

    Vivos Therapeutics Inc. (VVOS), a prominent name in the US stocks market, has been under the spotlight recently. This leading medical technology company has been making waves with its innovative diagnostic and treatment methods for patients grappling with various health conditions.

    Many of these conditions are associated with breathing-related sleep disorders emerging from certain dentofacial abnormalities.

    In the pre-market session today, Vivos Therapeutics Inc. (VVOS) showcased remarkable stock performance, with its price surging to $0.28, reflecting a substantial change of 51.46%.

    This substantial uptick in price was accompanied by robust trading activity, as the trading volume reached a significant 11,390,000 shares. These noteworthy market movements have undoubtedly captured the attention of investors, signaling potential market enthusiasm and heightened anticipation for the trading day ahead.

    Recent Happenings

    October 4, 2023, Vivos Therapeutics has announced forging strategic collaborations and agreements that not only expand its product line but also create promising revenue opportunities.

    The company publicized two key strategic agreements, which are expected to add potentially significant new revenue opportunities for Vivos, as well as airway-focused expertise and potential cost savings for Vivos-trained providers.

    Collaborations with Ormco and On Demand Orthodontist

    One of these collaborations involves Ormco, a division of publicly-traded Envista Holdings Corporation, and On Demand Orthodontist (ODO).

    Ormco, recognized for its exceptional products and customer service, has helped doctors treat more than 20 million patients in over 140 countries. Their Spark™ Clear Aligners are rapidly becoming the go-to clear aligner of choice for orthodontic specialists.

    As part of this agreement, Vivos and Ormco will embark on joint marketing and sales support from each company’s field sales teams. This is expected to facilitate faster treatment times and improved predictability for positive clinical outcomes for Vivos patients using Vivos CARE devices with Spark Aligners.

    The new agreement with ODO, on the other hand, provides a service to Vivos providers featuring direct access and case collaboration with airway-focused orthodontic specialists who are available to help optimize clinical outcomes for Vivos cases.

    The Way Forward for Vivos Therapeutics

    Despite the challenges posed by the larger economic and market environment, Vivos Therapeutics has positioned itself to achieve revenue growth and, ultimately, cash flow positive operations and profitability in the foreseeable future.

    With their innovative, evidence-based technology and a network of trained providers, they remain committed to their core mission of addressing the crisis of sleep apnea and breathing-related sleep issues. This makes Vivos a key player to watch in the US stocks market.

  • What Is Hurting VVOS Stock In Premarket Session?

    What Is Hurting VVOS Stock In Premarket Session?

    Pre-market trading showed shares of Vivos Therapeutics Inc. (VVOS) down by 10.58% at $4.65. Vivos stock closed the last session at $5.20, increasing 23.52% or $0.99. VVOS stock fluctuated between $4.42 and $5.45 during trading. During the day, 7.33 million shares of VVOS stock exchanged hands, exceeding the company’s normal 50-day daily volume of 0.15 million and exceeding its regular volume of 0.23 million for the year so far.

    In the past week, VVOS stock has moved up 7.66% while it has lost -15.72% in the past six months. VVOS stock has decreased -43.54% over the last three months, while so far this year it has returned -12.01%. In the last session, VVOS stock gained value on encouraging patient outcome news, but it seems profit taking has hurt the stock in the premarket session today.

    Why did the stock price of VVOS rise?

    Medical Technology Company Vivos develops and commercializes innovative diagnostics and treatment options for adult patients suffering from sleep disorders such as obstructive sleep apnea (OSA). In the Vivos treatment system for mild-to-moderate OSA, customized oral appliances and protocols are employed.

    According to VVOS, the Vivos System oral appliance technology is the first non-invasive, non-pharmacological, non-surgical, and cost-effective non-surgical treatment option for mild-to-moderate OSA. Adult and child orthodontic appliances are also available through VVOS. Over 1,200 dentists have successfully used VVOS’ oral appliances with more than 17,000 patients worldwide.

    According to Vivos, new data is available from an independent research study regarding its proprietary Vivos treatment for addressing dental tissue anomalies and dentofacial malformations which are associated with OSA and other debilitating conditions.

    Key findings of the data include:

    • The vast majority of OSA patients surveyed (97 percent) reported that the Vivos treatment had achieved their desired outcome.
    • More than half or 63% of respondents surveyed said their dentist provides them with the best advice on finding a lasting solution to OSA.
    • About one-third or 29% of patients surveyed reported searching for non-surgical treatment options for OSA.

    What VVOS offers?

    Patients are frequently seeking a significant reduction in OSA and related symptoms with Vivos (VVOS), as CPAP satisfaction and compliance rates remain low. The VVOS noted that some studies show CPAP usage rates of 30 to 60 percent and that OSA may become chronic, life-threatening comorbidities if untreated. Vivos treatment, on the other hand, typically takes 12 to 24 months to complete, after which patients no longer require ongoing treatment.